NCT01827982View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy
Interventions
DRUG

JNJ-54861911 1mg

JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.

DRUG

JNJ-54861911 3 mg

JNJ-54861911 3 mg will be administered as a single oral dose.

DRUG

JNJ-54861911 9 mg

JNJ-54861911 9 mg will be administered as a single oral dose.

DRUG

JNJ-54861911 27 mg

JNJ-54861911 27 mg will be administered as a single oral dose.

DRUG

JNJ-54861911 81 mg

JNJ-54861911 81 mg will be administered as a single oral dose.

DRUG

JNJ-54861911 160 mg

JNJ-54861911 160 mg will be administered as a single oral dose.

DRUG

JNJ-54861911 tbd

The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.

DRUG

JNJ-54861911 9 mg

Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.

DRUG

Placebo

Matching placebo will be given as a single oral dose.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01827982 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo | Biotech Hunter | Biotech Hunter